ImmunoGen, Inc.
Feb 2, 2017
PDF

ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

The webcasts will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and is in Phase¬†1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

Investor Contact:
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com
or
Media Contacts:
ImmunoGen, Inc.
Amy Reilly, 781-895-0138
amy.reilly@immunogen.com
or
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media